1. James Parkinson, Member of the Royal College of Surgeons. An Essay on the Shaking Palsy. J of Neuropsychiatr Clin Neurosci. 2002;14(2):223-36. [DOI:10.1176/jnp.14.2.223] [PMID]

2. Kempster PA, Hurwitz B, Lees AJ. A new look at James Parkinson's Essay on the Shaking Palsy. Neurology. 2007;69(5):482-5. [DOI:10.1212/01.wnl.0000266639.50620.d1] [PMID]

3. Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. J Neur Trans. 2017;124(8):901-5. [DOI:10.1007/s00702-017-1686-y] [PMID]

4. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatr. 2000;69(3):308-12. [DOI:10.1136/jnnp.69.3.308] [PMID] []

5. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr. 2008;79(4):368-76. [DOI:10.1136/jnnp.2007.131045] [PMID]

6. Alves G, Forsaa EB, Pedersen KF, Gjerstad MD, Larsen JP. Epidemiology of Parkinson's disease. J Neurol. 2008;255(5):18-32. [DOI:10.1007/s00415-008-5004-3] [PMID]

7. Hussain G, Rasul A, Anwar H, Sohail MU, Kamran SKS, Baig SM, et al. Epidemiological data of neurological disorders in Pakistan and neighboring countries: a review. Pakistan J Neurolog Sci. 2017;12(4):52-70.

8. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Eng J Med. 2003;348(14):1356-64. [DOI:10.1056/NEJM2003ra020003] [PMID]

9. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's Disease in a Japanese City. Arch Neurol. 1983;40(3):151-4. [DOI:10.1001/archneur.1983.04050030045008] [PMID]

10. Kurland L. Epidemiology: incidence, geographic distribution and genetic considerations. Pathogen Treat Parkinson. 1958:5-43.

11. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-35. [DOI:10.1016/S1474-4422(06)70471-9] [PMID]

12. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: A systematic review and meta-analysis. Movement Disorders. 2014;29(13):1583-90. [DOI:10.1002/mds.25945] [PMID]

13. Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292-300. [DOI:10.1159/000445751] [PMID]

14. Roohani M, Ali Shahidi G, Miri S. Demographic study of parkinson's disease in Iran: Data on 1656 cases. Iran J Neurol. 2011;10(1-2):19-21.

15. Argüelles JL, Borroto Bermudez L, Sosa Aguila L, Rodriguez Carbajal A. Prevalence of Parkinson's disease in an urban area of Cienfuegos city. Int J Fam Commun Med. 2019;3(1):12-4. [DOI:10.15406/ijfcm.2019.03.00121]

16. Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA. Estimation of Parkinson's Disease Prevalence and Its Geographical Variation in Iran. J Mazandaran Univ Med Sci. 2021;31(200):113-24.

17. Salari M, Mirmosayyeb O, Etemadifar M, Shaygannejad V, Khorvash F, Najafi MR, et al. Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran. Iran J Neurol. 2018;17(1):6-10.

18. Durmus H, Gokalp MA, Hanagasi HA. Prevalence of Parkinson's disease in Baskale, Turkey: a population based study. Neurolog Sci. 2015;36:411-3. [DOI:10.1007/s10072-014-1988-x] [PMID]

19. El-Tallawy HN, Farghaly WM, Shehata GA, Rageh TA, Hakeem NMA, Hamed MAA, et al. Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. Neuropsychiatr Dis Treat. 2013;12:1821-6. [DOI:10.2147/NDT.S48318] [PMID] []

20. Thiel M.F, Jost W.H. Sex and Gender Differences in Parkinson's Disease and the Conclusions we should Draw. J Neurol Disord 2024; 12:585.

21. Maclagan LC, Marras C, Sewell IJ, Wu CF, Butt DA, Tu K, et al. Trends in health service use among persons with Parkinson's disease by rurality: A population-based repeated cross-sectional study. PLoS One. 2023;18(5):12-20. [DOI:10.1371/journal.pone.0285585] [PMID] []

22. Chen CC, Chen TF, Hwang YC, Wen YR, Chiu YH, Wu CY, et al. Different prevalence rates of Parkinson's disease in urban and rural areas: a population-based study in Taiwan. Neuroepidemiol. 2009;33(4):350-7. [DOI:10.1159/000254572] [PMID]

23. Llibre-Guerra JJ, Prina M, Sosa AL, Acosta D, Jimenez-Velazquez IZ, Guerra M, et al. Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study. Lancet Region Health Am. 2022;7:12-20. [DOI:10.1016/j.lana.2021.100136] [PMID] []

24. Willis AW, Evanoff BA, Lian M, Galarza A, Wegrzyn A, Schootman M, et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol. 2010;172(12):1357-63. [DOI:10.1093/aje/kwq303] [PMID] []

25. Tarsy D. Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease. Jama. 2012;307(21):2305-14. [DOI:10.1001/jama.2012.4829] [PMID]

26. Malek N, Bajaj N, Barker R, Ben-Shlomo Y, Burn D, Foltynie T, et al. FAMILY HISTORY IN YOUNG ONSET PARKINSON'S DISEASE. J Neurol Neurosurg Psychiat. 2013;84(11):2-12. [DOI:10.1136/jnnp-2013-306573.160]

27. Rybicki BA, Johnson CC, Peterson EL, Kortsha GX, Gorell JM. A family history of Parkinson's disease and its effect on other PD risk factors. Neuroepidemiology. 1999;18(5):270-8. [DOI:10.1159/000026222] [PMID]

28. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 2001;1:12-20.

29. Golbe LI, Leyton CE. Life expectancy in Parkinson disease. J Psychiatr Res. 2018;91(22):991-2. [DOI:10.1212/WNL.0000000000006560] [PMID]

30. Aggarwal S, Paul G, Paul BS, Mahendru D, Goyal S. Factors Affecting Adherence to Pharmacotherapy in Parkinson's Disease. Ann Indian Acad Neurol. 2021;24(6):879-84.